High expression of MZF1 correlated with poor prognoses in prostate cancer and kidney cancer, whereas SCAND1 and MZF1 expression correlate with better prognoses in pancreatic cancer and stage III head and neck cancers [43]. Here, SCAND1 is linked to prostate carcinoma.